Longeveron Announces Exercise Of Warrants For $6.2M Gross Proceeds
Longeveron Announces Exercise Of Warrants For $6.2M Gross Proceeds
Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its Class A common stock having an exercise price of $2.35 per share, originally issued in October 2023 and April 2024. The issuance or resale of the shares of Class A common stock issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on Form S-1 (File Nos. 333-275578 and 333-278073). The gross proceeds to the Company from the exercise of the existing warrants are expected to be approximately $6.2 million, prior to deducting placement agent fees and estimated offering expenses payable by the Company.
Longeveron Inc.（納斯達克股票代碼：LGVN）（“Longeveron” 或 “公司”）是一家臨床階段的生物技術公司，爲左心發育不全綜合症（HLHS）、阿爾茨海默氏病和衰老相關虛弱症等危及生命的慢性衰老相關疾病開發細胞療法。該公司今天宣佈，它已就行使某些現有認股權證達成最終協議，共購買2,399,744份認股權證其行使價爲每股2.35美元的A類普通股股票，最初於2023年10月和2024年4月發行。行使現有認股權證時可發行的A類普通股的發行或轉售根據S-1表格（文件編號333-275578和333-278073）上的有效註冊聲明進行登記。在扣除配售代理費和公司應付的預計發行費用之前，公司通過行使現有認股權證獲得的總收益預計約爲620萬美元。
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
H.C. Wainwright & Co. 擔任本次發行的獨家配售代理。
In consideration for the immediate exercise of the existing warrants for cash and the payment of $0.125 per new warrant, the Company will issue new unregistered warrants to purchase up to an aggregate of 4,799,488 shares of Class A common stock. The new warrants will be immediately exercisable at an exercise price of $2.35 per share. The new warrants to purchase 2,399,744 shares of Class A common stock will have a term of five years from the issuance date, and the new warrants to purchase 2,399,744 shares of Class A common stock have a term of twenty-four months from the issuance.
作爲立即行使現有現金認股權證和支付每份新認股權證0.125美元的考慮，公司將發行新的未註冊認股權證，購買總額不超過4,799,488股A類普通股。新的認股權證將立即以每股2.35美元的行使價行使。購買2399,744股A類普通股的新認股權證的期限爲自發行之日起五年，購買2399,744股A類普通股的新認股權證自發行之日起有效期爲二十四個月。
The offering is expected to close on or about April 18, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for its ongoing clinical and regulatory development of Lomecel-B for the treatment of several disease states and indications, including HLHS and Alzheimer's disease, obtaining regulatory approvals, capital expenditures, working capital and other general corporate purposes.
此次發行預計將於2024年4月18日左右結束，但須滿足慣例成交條件。公司打算將本次發行的淨收益用於正在進行的Lomecel-B臨床和監管開發，用於治療包括HLHS和阿爾茨海默氏病在內的多種疾病狀態和適應症，獲得監管部門的批准、資本支出、營運資金和其他一般公司用途。
譯文內容由第三人軟體翻譯。